HutchMed (Nasdaq/AIM: HCM; HKEX:13) is a pioneering biopharmaceutical company that is dedicated to researching, developing, and distributing targeted therapies and immunotherapies to fight cancer and immune-related diseases. With over 4,600 employees, including a team of 1,500 specialized in oncology/immunology, HutchMed has been able to move twelve of its cancer drug candidates from discovery to clinical trials worldwide. Three of their oncology drugs have even been approved and are now being sold. To learn more, please visit www.hutchmed.com or follow them on LinkedIn.